These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6158076)

  • 1. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of procainamide hydrochloride in dogs.
    Papich MG; Davis LE; Davis CA; McKiernan BC; Brown SA
    Am J Vet Res; 1986 Nov; 47(11):2351-8. PubMed ID: 2431636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution of N-acetylprocainamide in rats.
    Yacobi A; Stampfli HF; Lai CM; Kamath BL
    Drug Metab Dispos; 1981; 9(3):193-5. PubMed ID: 6166443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
    Baer DT; Barkus JC
    Res Commun Chem Pathol Pharmacol; 1977 Jun; 17(2):333-6. PubMed ID: 17895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog.
    Lertora JJ; King LW
    J Pharmacol Exp Ther; 1986 Sep; 238(3):893-9. PubMed ID: 2427689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of N-acetylprocainamide from mixed diet in rats.
    Kamath BL; Yacobi A; Gupta SD; Stampfli H; Durrani M; Lai CM
    Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):299-308. PubMed ID: 6166034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the fate of tyramine in dogs: the effect of monoamine oxidase inhibition, portafemoral shunt and coronary artery ligation on the kinetics of tyramine.
    Faraj BA; Dayton PG; Camp VM; Wilson JP; Malveaux EF; Schlant RC
    J Pharmacol Exp Ther; 1977 Feb; 200(2):384-93. PubMed ID: 839443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol.
    Lertora JJ; King LW; Donkor KA
    Angiology; 1986 Dec; 37(12 Pt 2):939-49. PubMed ID: 2433968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
    Kates RE; Jaillon P; Rubenson DS; Winkle RA
    Clin Pharmacol Ther; 1980 Jul; 28(1):52-7. PubMed ID: 6156049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.
    Dangman KH; Hoffman BF
    J Pharmacol Exp Ther; 1981 Jun; 217(3):851-62. PubMed ID: 6164783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model].
    Liu XD; Deng N; Huang SK
    Yao Xue Xue Bao; 1991; 26(10):725-32. PubMed ID: 1726674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.